Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine adjunctive therapy study in CDKL5 deficiency disorder
NL-OMON60042Phase 3Active, not recruiting
- Sponsor
- Zogenix, Inc.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in CDKL5 deficiency disorder (CDD), sponsored by Zogenix, Inc. Started Nov 2023; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on NL-OMON60042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60042.